Separating facts from fear and revisiting lessons in preparedness in the context of HMPV

Main Article Content

Manya Prasad
https://orcid.org/0000-0002-1239-0013

Abstract

The recent reports of rising Human Metapneumovirus (HMPV) cases in China have reignited concerns about the global readiness to address respiratory virus outbreaks. Although HMPV has recently garnered significant media attention, it is crucial to avoid being influenced by sensationalized coverage. While HMPV is not new and its spread is largely limited to vulnerable populations, such episodes serve as a timely reminder of the factors influencing pandemic potential and the critical importance of preparedness.


Human Metapneumovirus (HMPV) is a respiratory virus that causes symptoms similar to the common cold and influenza. These include fever, cough, nasal congestion, and difficulty breathing. The incubation period of HMPV ranges from 3 to 6 days, and symptoms typically resolve within 5 to 10 days for most healthy individuals. Young children, particularly those under six months, and older adults with weakened immune systems or chronic respiratory conditions, such as Chronic Obstructive Pulmonary Disease (COPD), are at a higher risk of developing severe complications like pneumonia. The virus spreads through respiratory droplets and contaminated surfaces, particularly in crowded settings (1). Despite its widespread circulation, most HMPV infections are mild, and re-infections are common throughout life, generally presenting with mild symptoms. Severe cases are rare and primarily affect those with compromised immune systems or underlying health conditions (2).

Downloads

Download data is not yet available.

Article Details

Section

Editorial

How to Cite

1.
Separating facts from fear and revisiting lessons in preparedness in the context of HMPV. JEFI [Internet]. 2025 Mar. 31 [cited 2025 Apr. 19];3(1):03-5. Available from: https://efi.org.in/journal/index.php/JEFI/article/view/71

References

1. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis. 2003;187(5):785–90. DOI: https://doi.org/10.1086/367901

2. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719–24. DOI: https://doi.org/10.1038/89098

3. World Health Organization. Pandemic preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits. Geneva: WHO; 2011. Available from: https://www.who.int/influenza/pip/en/ (Accessed on 25-03-2025)

4. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, et al. Co-morbidities, outcomes, and care among COVID-19 patients. Lancet. 2021;398(10302):1437–8.

5. Centers for Disease Control and Prevention. Basics of COVID-19. Atlanta: CDC; 2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/your-health/about-covid-19.html (Accessed on 25-03-2025)

6. Shi T, Arnott A, Semogas I, Falsey AR, Openshaw PJ, Wedzicha JA, et al. The global burden of respiratory syncytial virus disease in adults: A systematic review and meta-analysis. Eur Respir Rev. 2022;31(166):210239.

7. Wang X, Li Y, Ou2019Brien KL, Madhi SA, Widdowson MA, Byass P, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years: A systematic review and meta-analysis. Lancet. 2020;398(10303):1441–51.

8. Centers for Disease Control and Prevention. Human metapneumovirus (HMPV): Clinical features. Atlanta: CDC; 2023. Available from: https://www.cdc.gov/hmpv/clinical.html (Accessed on 25-03-2025)